MBRX - Moleculin announces proposed underwritten public offering

Moleculin Biotech (MBRX) announces that it intends to offer and sell shares in an underwritten public offering.The company plans to use the net proceeds of the offering to fund its planned clinical trials and preclinical programs among other things.As part of this offering, Moleculin intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares.The company did not provide further details on the potential offering.Oppenheimer & Co. is acting as the sole book-running manager for the proposed offering.

For further details see:

Moleculin announces proposed underwritten public offering